Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SECRET: Rivaroxaban in Cerebral Venous Thrombosis
NCT03178864Phase 2Completed
- Sponsor
- University of British Columbia
- Start
- Mar 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Cerebral venous thrombosis (CVT) comparing Rivaroxaban with Standard of Care (2 arms). Primary endpoint: Composite of all-cause mortality, symptomatic intracranial bleeding, major extracranial bleeding at 180 days. Started Mar 2019; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Cerebral venous thrombosis (CVT)
Beyond the preview
Go deeper on NCT03178864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03178864.